No abstract

Purpose: The study aims to explore the benefits of digitisation and provide insights into how companies can successfully implement digital strategies to improve their marketing and logistics functions.   Theoretical framework: The study utilizes a comparative analysis of information systems used by manufacturing and trading enterprises to understand the digitalisation process.   Design/methodology/approach: The research methodology involves defining the scope of digitalisation, assessing the current state, developing a digitalisation strategy, planning the implementation, executing the implementation, monitoring progress, optimizing the process, and continuously reviewing and improving.   Findings: The proposed algorithm consists in defining the scope of digitalisation, assessing the current state, developing a digitalisation strategy, planning the implementation, executing the implementation, monitoring progress, optimising the process, and continuously reviewing and improving. The effectiveness of digitalisation is evaluated using objective mathematical models and Key Performance Indicators specific to the goals of the digitalisation process.   Research, Practical & Social implications: The article provides an example of how the mathematical model for digitalisation can be implemented in a real-world scenario. The mathematical model is represented as an equation that maximises the value generated from the digitalisation of marketing and logistics activities subject to constraints such as budget, efficiency improvement, and customer satisfaction improvement.   Originality/value: This article provides insights into the digitisation of marketing and logistics activities in manufacturing and trading enterprises. It offers a systematic approach and a mathematical model for evaluating and implementing digitalisation strategies, contributing to the existing knowledge on digital transformation in the business domain.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an uncommon disease characterized by heterogeneous clinical findings, absence of specific laboratory markers and good response to treatment. Typically CIDP manifests as weakness of varying severity, from minimal paresis to plegia, as well as symmetrical loss of sensitivity in all limbs, a distinctive clinical feature of CDL is the involvement of both proximal and distal parts of extremities. At the same time, there is a large number of atypical CIDP variants, clinically similar to other chronic disimmune neuropathies. Neuroimaging findings typically include involvement of the cauda equina, brachial, and lumbar plexus. The patient sought medical help complaining of weakness and loss of sensation in the extremities. This clinical case illustrates a combined involvement of cranial and spinal nerves, as well as spinal cord and brain in a patient with chronic inflammatory demyelinating polyneuropathy.

No abstract

Objective: to evaluate the efficacy and safety of cladribine tablets as a treatment for immune reconstitution of highly active multiple sclerosis (HAMS) in general clinical practice.Patients and methods. 34 patients with HAMS who were followed up at the Moscow Multiple Sclerosis Center in 2018–2021 received two full treatment courses. HAMS diagnosis was established in the presence of two or more exacerbations per year without treatment or one exacerbation in patients receiving pathogenetic treatment in the presence of concomitant manifestations of the activity of the pathological process on MRI. Before initiation of cladribine therapy, the median exacerbation rate was 2.3 per year, i.e., 34 patients per year had a total of 78 exacerbations.Results and discussion. Only two clinical exacerbations were registered (one each in the first and second year) during two years of treatment among all 34 patients, the average frequency of exacerbations was 0.05 per year; in three cases, a subclinical exacerbation was noted - new Gd+ lesions on T2-weighted images on MRI, the total number of events was 0.15 per year. No significant adverse events were reported.Conclusion. Cladribine tablets are a highly effective and safe treatment option for HAMS.